The Global Small-Molecule APIs Market was valued at US$ 20.07 billion in 2021 and is predictable to reach US$ 53.79 billion by 2030 which is projected to attain a CAGR of 11.6 % during the forecast period from 2021- 2030.
Small molecule active pharmaceutical ingredient (API) is referred as a low molecular weight organic compound having a size of nearly 1 nm assisting in the regulation of the biological process. The small molecules are administered orally and owing to their lesser molecular weight, the body absorbs active solution quickly. It is a vital element in the pharmaceuticals industry owing to its effective treatment, prevention, and diagnosis of numerous diseases.
The increasing prevalence of diseases such as infections, cancer, and cardiovascular is anticipated for the global small molecule API market growth during the forecast period. In addition, patents expiry of top-selling pharmaceuticals and R&D & manufacturing of small molecule APIs are also the prime reasons augmenting the market rise during the forecast period. Technological advancements in the manufacturing sector enhance the rate of generic drugs & small molecule API production. Furthermore, awareness of the diseases & their treatments among the people, R&D activities for new drug development, improving the healthcare facilities, the rise of the geriatric population are positively influencing the small molecule API market growth.
However, strict government regulations, financial crises, and global recession are sternly affecting the market growth during the forecast period. In addition, lack of skilled & trained healthcare personnel, higher cost associated with small-molecule API, huge initial investment, and lack of compensation policy is also restraining the market expansion.
The Global Small molecule APIs Market is segmented by product, type, application, end-user, and region. Based on product, it is categorized into contract and captive. By type, it is bifurcated into the chemical process and biological procedures. Application of small molecule API segments into cardiovascular, dermatology, urology, ophthalmology, metabolic, respiratory, and others. By end-user, it bifurcates into ambulatory surgical centers, hospitals, and others. Based on regional insights, the global small molecule APIs market is categorized into North America (US, Canada, Mexico, Rest of America), Asia Pacific (India, China, Rest of Asia Pacific), Europe (UK, Germany, Russia, Rest of Europe) and Rest of the world (Latin America and Middle East & Africa).
North America is dominated the market owing to the increasing prevalence of chronic diseases and the wide availability of advanced technologies & reimbursement policies in the region. Asia Pacific region is also attributed to grow at a higher CAGR owing to awareness for health care and development of health infrastructures in the region during the forecast period.
Prominent players inducing the Global Small Molecule APIs Market are Lonza, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Albemarle Corporation, BASF SE, Gilead Sciences Inc., Baxter International Inc., Celgene Corporation, Recipharm AB, Glenmark Pharmaceuticals Limited, AbbVie Contract Manufacturing, Bayer AG, CordenPharma International, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Aesica Pharmaceuticals Ltd., Cambrex Corporation, Gland Pharma Limited, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Piramal Pharma Solutions, Evonik Industries AG, Siegfried AG, Aurinia Pharmaceuticals Inc., and Patheon among others.
Segmentation and Scope of the Global Small Molecule APIs Market
Global Small Molecule APIs Market is segmented by product, type, application, end-user, and region.
Rest of World
Middle East & Africa
Prominent players in the Global Softgel Capsules Market among other includes